Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Avalo Therapeutics

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Announces Participation in September Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX TRML
Avalo Reports 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX SLRN
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX HRZN
Avalo Enters into Agreement to Divest AVTX-800 Series
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Participate in SVB Securities Therapeutics Forum
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Present at the Jefferies Healthcare Conference
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Present at ATS 2023 Respiratory Innovation Summit
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Reports 2022 Financial Results and Provides Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.